Paliperidone Palmitate 3-month Versus 1-month Formulation In Patients With Schizophrenia: A Randomized, Double-blind, Noninferiority Study

被引：0
|
作者：
Savitz, Adam [1 ]
Xu, Haiyan [1 ]
Gopal, Srihari [1 ]
Nuamah, Isaac [1 ]
Ravenstijn, Paulien [2 ]
Janik, Adam [3 ]
Schotte, Alain [2 ]
Hough, David [1 ]
Fleischhacker, Wolfgang W. [4 ]
机构：
[1] Johnson & Johnson Pharmaceut R&D, Neurosci, Titusville, NJ USA
[2] Johnson & Johnson Pharmaceut R&D, Neurosci, Beerse, Belgium
[3] Janssen Cilag, Neurosci, Warsaw, Poland
[4] Innsbruck Med Univ, Dept Psychiat & Psychotherapy, Innsbruck, Austria
来源：
BIOLOGICAL PSYCHIATRY | 2016年 / 79卷 / 09期
关键词：
Paliperidone; 1; monthly; 3; schizophrenia; relapse; PANSS;
D O I：
暂无
中图分类号：
Q189 [神经科学];
学科分类号：
071006 ;
摘要：
1034
引用
收藏
页码：354S / 354S
页数：1
相关论文
共 50 条
  • [21] Predictors of achieving remission in schizophrenia patients treated with paliperidone palmitate 3-month formulation
    Nash, Abigail, I
    Turkoz, Ibrahim
    Savitz, Adam J.
    Mathews, Maju
    Kim, Edward
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2019, 15 : 731 - 737
  • [22] Potential Biomarkers of Impending Schizophrenia Relapse: Exploratory Analysis of a Randomized, Double-Blind, Placebo-Controlled, Phase-3 Study of Paliperidone Palmitate 3-Month Formulation
    Gopal, Srihari
    Furey, Maura
    Hibar, Derrek
    Kolb, Hartmuth
    Saad, Ziad
    Savitz, Adam
    Triana-Baltzer, Gallen
    BIOLOGICAL PSYCHIATRY, 2017, 81 (10) : S126 - S127
  • [23] Efficacy and Safety of Paliperidone Palmitate 6-Month versus Paliperidone Palmitate 3-Month Long-Acting Injectable in European Patients with Schizophrenia: A Post Hoc Analysis of a Global Phase-3 Double-Blind Randomized Non-Inferiority Study
    Giron-Hernandez, Cesar
    Han, Joong Hee
    Alberio, Roberta
    Singh, Arun
    Garcia-Portilla, Maria Paz
    Pompili, Maurizio
    Knight, R. Karl
    Richarz, Ute
    Gopal, Srihari
    Antunes, Jose
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2023, 19 : 895 - 906
  • [24] Efficacy and safety of paliperidone palmitate 3-monthly versus 1-monthly formulation in Asian patients with schizophrenia: Subgroup analysis of a randomized, double-blind, noninferiority study
    Savitz, A.
    Gopal, S.
    Xu, H.
    Zhuo, J.
    Yu, L.
    Nuamah, I.
    Wu, C.
    Hough, D.
    Mathews, M.
    Feng, Y.
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2016, 19 : 201 - 201
  • [25] Efficacy and safety of paliperidone palmitate 3-month formulation in Latin American patients with schizophrenia: A subgroup analysis of data from two large phase 3 randomized, double-blind studies
    Savitz, Adam J.
    Xu, Haiyan
    Gopal, Srihari
    Nuamah, Isaac
    Mathews, Maju
    Soares, Bernardo
    BRAZILIAN JOURNAL OF PSYCHIATRY, 2019, 41 (06) : 499 - 510
  • [26] Effect of two long-acting treatments, the paliperidone palmitate 1-month and 3-month formulations on caregiver burden in European patients with schizophrenia
    Hargarter, L.
    Gopal, S.
    Xu, H.
    McQuarrie, K.
    Savitz, A.
    Nuamah, I.
    Woodruff, K.
    Mathews, M.
    EUROPEAN PSYCHIATRY, 2017, 41 : S198 - S198
  • [27] Pharmacokinetic-Pharmacodynamic Characterization of Relapse Risk for Paliperidone Palmitate 1-Month and 3-Month Formulations
    Russu, Alberto
    Savitz, Adam
    Mathews, Maju
    Gopal, Srihari
    Feng, Yu
    Samtani, Mahesh N.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2019, 39 (06) : 567 - 574
  • [28] Paliperidone palmitate 3-month formulation and sexual dysfunction in young schizophrenic patients
    Plasencia Garcia De Diego, B. O.
    Romero Guillena, S. L.
    Gotor Sanchez-Luengo, F.
    EUROPEAN PSYCHIATRY, 2019, 56 : S261 - S261
  • [29] Use of paliperidone palmitate 3-month formulation in clinical practice: an extended study
    Romero Guillena, S. L.
    Plasencia Garcia de Diego, B. O.
    Gotor Sanchez-luengo, F.
    Garcia Salguero, M.
    EUROPEAN PSYCHIATRY, 2019, 56 : S264 - S264
  • [30] Effects of Paliperidone Palmitate 3 Month and 1 Month Formulations on Personal and Social Performance Scores in Patients with Schizophrenia: Results from a Randomized, Multicenter, Double-Blind, Non-inferiority Study
    Savitz, Adam
    Xu, Haiyan
    Mathews, Maju
    Nuamah, Isaac
    Gopal, Srihari
    BIOLOGICAL PSYCHIATRY, 2016, 79 (09) : 212S - 212S
12345